CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 122 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2023. The put-call ratio across all filers is 1.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,625,000 | -31.2% | 74,288 | +0.3% | 0.00% | -40.0% |
| Q2 2023 | $2,361,000 | +30.6% | 74,038 | -0.7% | 0.01% | +25.0% |
| Q1 2023 | $1,808,000 | -23.9% | 74,538 | -0.7% | 0.00% | -20.0% |
| Q4 2022 | $2,375,000 | +12.1% | 75,038 | -0.0% | 0.01% | -16.7% |
| Q3 2022 | $2,118,000 | +6.2% | 75,068 | -0.7% | 0.01% | +20.0% |
| Q2 2022 | $1,994,000 | -25.8% | 75,568 | -0.8% | 0.01% | -16.7% |
| Q1 2022 | $2,689,000 | +13.4% | 76,168 | +3.6% | 0.01% | +20.0% |
| Q4 2021 | $2,371,000 | +11.1% | 73,488 | +2.3% | 0.01% | -16.7% |
| Q3 2021 | $2,134,000 | +15.4% | 71,844 | 0.0% | 0.01% | +20.0% |
| Q2 2021 | $1,850,000 | +102.4% | 71,844 | +8.0% | 0.01% | +66.7% |
| Q1 2021 | $914,000 | +21.5% | 66,544 | +46.8% | 0.00% | 0.0% |
| Q4 2020 | $752,000 | – | 45,325 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |